Cancer Res Treat
October 2015
Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Hull, UK.
Purpose: We report the outcomes of patients treated with palliative radiotherapy (pRT) to the primary tumour in the context of well-controlled metastatic disease after initial chemotherapy.
Materials And Methods: Clinical records of 132 patients with metastatic esophago-gastric (OG) cancer treated with palliative chemotherapy (pCT) between January 2009 and June 2013 were reviewed. Ninetyseven patients had responding or stable disease after 3 months of chemotherapy, of whom 53 patients received pRT to the primary tumour after initial chemotherapy in the presence of well-controlled metastatic disease (group A, pCT-RT).
Br J Cancer
March 2015
Leeds Institute of Cancer and Pathology, University of Leeds, Bexley Wing, St James University Hospital, Beckett Street, Leeds, West Yorkshire LS9 7TF, UK.
Background: The rising financial burden of cancer on health-care systems worldwide has led to the increased demand for evidence-based research on which to base reimbursement decisions. Economic evaluations are an integral component of this necessary research. Ascertainment of reliable health-care cost and quality-of-life estimates to inform such studies has historically been challenging, but recent advances in informatics in the United Kingdom provide new opportunities.
View Article and Find Full Text PDFQual Life Res
May 2015
Psychosocial Oncology and Clinical Practice Research Group, St James' Institute of Oncology, University of Leeds, Level 3, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK,
Background: In the UK, demonstration of patient and public involvement (PPI) is now a funding requirement. Despite advice being available to researchers regarding PPI, levels of engagement are variable. Patient involvement has been at the core of the Leeds Psychosocial Oncology and Clinical Practice Research Group since 2007 when a local Research Advisory Group (RAG) was established.
View Article and Find Full Text PDFBreast Cancer Res
December 2015
Division of Hematology/Oncology, Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Introduction: Progression-free survival (PFS) and overall survival (OS) endpoints often only weakly correlate. This analysis investigates how different progression events impact on OS, using data from two phase 3 studies with eribulin in women with advanced/metastatic breast cancer (MBC).
Methods: In Study 301, 1102 women with ≤2 prior chemotherapies for advanced/MBC were randomized to eribulin mesylate (1.
Cancer Manag Res
December 2014
Cancer Centre, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Trust, Birmingham, UK.
Purpose: Stenting of the biliary tree is a common palliative procedure to relieve obstructive jaundice in advanced malignancy. Although effective in relief of biliary obstruction and palliation of symptoms, little information is available on predictive factors for survival post-procedure. This retrospective study sought to assess factors influencing post-procedure survival in cancer patients after biliary stenting.
View Article and Find Full Text PDFJ Nucl Med
December 2014
St. James Institute of Oncology Level 1, Bexley Wing Leeds LS9 7TF, U.K. E-mail:
Ann Oncol
June 2015
Academic Unit of Elderly Care and Rehabilitation, University of Leeds, Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
Background: Frailty is a state of vulnerability to poor resolution of homeostasis following a stressor event, such as chemotherapy or cancer surgery. Better knowledge of the epidemiology of frailty could help drive a global cancer care strategy for older people. The aim of this review was to establish the prevalence and outcomes of frailty and pre-frailty in older cancer patients.
View Article and Find Full Text PDFInt J Radiat Oncol Biol Phys
November 2014
St James' Institute of Oncology, Leeds, United Kingdom. Electronic address:
Background: Cure of lung cancer is impossible without local tumour control. This can be compromised by accelerated repopulation of tumour cells during radiotherapy and chemotherapy. A strategy to minimise accelerated repopulation might improve local control.
View Article and Find Full Text PDFClin Oncol (R Coll Radiol)
November 2014
The Gray Institute for Radiation Oncology & Biology, Oxford, UK.
Eur Urol
May 2015
Department of Urology, Texas Health Presbyterian Hospital Dallas, Dallas TX, USA.
Background: The terminology and abbreviations used in urologic imaging have generally been adopted on an ad hoc basis by different speciality groups; however, there is a need for shared nomenclature to facilitate clinical communication and collaborative research.
Objective: This work reviews the current nomenclature for urologic imaging used in clinical practice and proposes a taxonomy and terminology for urologic imaging studies.
Design, Setting, And Participants: A list of terms used in urologic imaging were compiled from guidelines published by the European Association of Urology and the American Urological Association and from the American College of Radiology Appropriateness Criteria.
J Natl Cancer Inst
September 2014
Divisions of Genetics and Epidemiology (AJS, RC), Breast Cancer Research (AJS) and Radiotherapy (AH), Institute of Cancer Research, Sutton, UK; University of Manchester and Christie NHS Foundation Trust, Manchester, UK (JR); Gastrointestinal Unit, Royal Marsden Hospital, Sutton, UK (DC); Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK (IS); Cancer Research UK Medical Oncology Unit, St. Bartholomew's Hospital, London, UK (TAL); Cancer Centre, Mount Vernon Hospital, Middlesex, UK (PJH); St. James Institute of Oncology, Leeds, UK (DG); Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK (HHL); Bristol Haematology and Oncology Centre, Bristol, UK (SJF); Addenbrooke's Hospital, Cambridge, UK (MVW); Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK (BWH); Guy's and St. Thomas, London, UK (SJH); Department of Haematology, University College Hospital, London, UK (DCL); Southampton General Hospital, Southampton, UK (AB); Queen Elizabeth Hospital, Birmingham, UK (AMS). The England and Wales Hodgkin Lymphoma Follow-up Group includes the authors of this article plus: Gabriel Anghel, Lincoln Hospital; Brian Attock, North Devon District Hospital; Jane Barrett, Royal Berkshire Hospital; Andrew Bell, Poole Hospital; Kim Benstead, Cheltenham General Hospital; Eric M. Bessell, Nottingham University Hospital; Ashoke Biswas, Royal Preston Hospital; Norbert Blesing, Great Western Hospital, Swindon; Caroline Brammer, New Cross Hospital, Wolverhampton; Jill Brock, Clatterbridge Centre for Oncology; Alison Brownell, Queens Hospital, Romford; A. Murray Brunt, University Hospital of North Staffordshire; Peter B. Coates, Queen Elizabeth Hospital, King's Lynn; Matthew P. Collinson, Royal Cornwall Hospital; Neville Davidson, Essex County Hospital; Sian Davies, North Middlesex University Hospital; Ian Fentiman, Guy's Hospital; Eve Gallop-Evans, Velindre Hospital; Angel Garcia, Glan Clwyd Hospital; Andrew Goodman, Royal Devon and Exeter Hospital; Ad
Background: Modern treatment of Hodgkin's lymphoma (HL) has transformed its prognosis but causes late effects, including premature menopause. Cohort studies of premature menopause risks after treatment have been relatively small, and knowledge about these risks is limited.
Methods: Nonsurgical menopause risk was analyzed in 2127 women treated for HL in England and Wales at ages younger than 36 years from 1960 through 2004 and followed to 2003 through 2012.
Colorectal Dis
November 2014
Department of General Surgery, St James' Institute of Oncology, St James University Hospital, Beckett Street, Leeds, LS9 7T, UK.
Br J Oral Maxillofac Surg
October 2014
Evidence-Based Practice Research Centre (EPRC), Faculty of Health, Edge Hill University, St Helens Road, Ormskirk, L39 4QP and Consultant, Regional Maxillofacial Unit, University Hospital Aintree, Liverpool, L9 1AE, UK. Electronic address:
Although there are recommendations, there is little evidence about the rationale for the frequency and duration of review appointments for patients with cancer of the head and neck. We have recorded the pattern of follow-up in a tertiary cancer centre and its association with survival and recurrent disease. We used clinical letters and a prospectively maintained database to obtain details on 297 patients who were treated curatively for squamous cell carcinoma (SCC) of the oral cavity between 2005 and 2008.
View Article and Find Full Text PDFLancet Oncol
August 2014
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Background: The role of adjuvant bisphosphonates in early breast cancer is uncertain. We therefore did a large randomised trial to investigate the effect of the adjuvant use of zoledronic acid on disease-free survival (DFS) in high-risk patients with early breast cancer.
Methods: In the AZURE trial, an open-label, international, multicentre, randomised, controlled, parallel-group phase 3 trial, women (age ≥18 years) with stage II or III breast cancer were randomly assigned (1:1) by a central automated 24-h computer-generated telephone minimisation system (balanced for number of involved axillary lymph nodes, tumour stage, oestrogen receptor status, type and timing of systemic therapy, menopausal status, statin use, and treatment centre) to receive standard adjuvant systemic treatment alone (control group) or with 4 mg intravenous zoledronic acid every 3-4 weeks for six doses, then every 3 months for eight doses, followed by every 6 months for five doses, for a total of 5 years of treatment.
Ann Oncol
August 2014
Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge
Background: T-cell infiltration in estrogen receptor (ER)-negative breast tumours has been associated with longer survival. To investigate this association and the potential of tumour T-cell infiltration as a prognostic and predictive marker, we have conducted the largest study of T cells in breast cancer to date.
Patients And Methods: Four studies totalling 12 439 patients were used for this work.
Clin Oncol (R Coll Radiol)
August 2014
St James' Institute of Oncology, Leeds, UK. Electronic address:
The place of bevacizumab in the management of advanced non-small cell lung cancer (NSCLC) was reviewed. Particular reference has been made to the recent research on the systemic treatment of NSCLC indicating that treatment tailored to specifically identified morphology or genetic profile has recently changed practice. The result of this recent research means that bevacizumab has little, if any, place in the treatment of NSCLC.
View Article and Find Full Text PDFCancer Cell
June 2014
Haematopoietic Stem Cell Biology Laboratory, MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Departments of Cell and Molecular Biology, Medicine Huddinge, and Laboratory Medicine, Huddinge, Karolinska Institutet and Center for Hematology and Regenerative Medicine, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden. Electronic address:
Evidence for distinct human cancer stem cells (CSCs) remains contentious and the degree to which different cancer cells contribute to propagating malignancies in patients remains unexplored. In low- to intermediate-risk myelodysplastic syndromes (MDS), we establish the existence of rare multipotent MDS stem cells (MDS-SCs), and their hierarchical relationship to lineage-restricted MDS progenitors. All identified somatically acquired genetic lesions were backtracked to distinct MDS-SCs, establishing their distinct MDS-propagating function in vivo.
View Article and Find Full Text PDFMed Phys
May 2014
LIGHT Institute University of Leeds Leeds LS2 9JT, Division of Medical Physics, Leeds, United Kingdom and Institute of Medical Physics, School of Physics, University of Sydney, Australia.
Purpose: Flattening filter free (FFF) linear accelerators can increase treatment efficiency and plan quality. There are multiple methods of defining a FFF beam. The Elekta control system supports tuning of the delivered FFF beam energy to enable matching of the percentage depth-dose (PDD) of the flattened beam at 10 cm depth.
View Article and Find Full Text PDFTransl Oncol
February 2014
Academic Department of Radiation Oncology, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom ; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Background: Preclinical data have indicated the anti-epidermal growth factor receptor (EGFR) agent cetuximab (Erbitux) as a radiosensitizer in pancreatic cancer, but this has not been specifically addressed in a clinical study. We report the results of an original study initiated in 2007, where cetuximab was tested with radiotherapy (RT) alone in locally advanced pancreatic cancer in a phase II trial (PACER).
Methods: Patients (n = 21) received cetuximab loading dose (400 mg/m(2)) and weekly dose (250 mg/m(2)) during RT (50.
Med Phys
February 2014
Institute of Medical Physics, School of Physics, The University of Sydney, New South Wales 2006, Australia and Department of Medical Physics and Engineering, St. James Institute of Oncology, St. James University Hospital, Leeds LS9 7TF, United Kingdom.
Purpose: Electronic portal imaging devices (EPIDs) have proven to be useful tools for measuring several parameters of interest in linac quality assurance (QA). However, a method for measuring linac photon beam energy using EPIDs has not previously been reported. In this report, such a method is devised and tested, based on fitting a second order polynomial to the profiles of physically wedged beams, where the metric of interest is the second order coefficient α.
View Article and Find Full Text PDFBr J Oral Maxillofac Surg
April 2014
Department of Oral and Maxillofacial Surgery, Medical Faculty, RWTH Aachen University, Aachen, Germany.
The scapula free flap is often the first choice for reconstruction of bony defects of the facial skeleton. However, the vascularised rib as part of a free rib osteomyocutaneous flap may be a suitable second choice. We have investigated the morphology and clinical dimensions of the 7th rib and the scapula, and the ability of the available bone to carry dental implants.
View Article and Find Full Text PDFJ Med Ethics
August 2014
Rotman Institute of Philosophy, University of Western Ontario, London, Canada.
The use of charged-particle radiation therapy (CPRT) is an increasingly important development in the treatment of cancer. One of the most pressing controversies about the use of this technology is whether randomised controlled trials are required before this form of treatment can be considered to be the treatment of choice for a wide range of indications. Equipoise is the key ethical concept in determining which research studies are justified.
View Article and Find Full Text PDFEJC Suppl
September 2013
University of Leeds and St James' Institute of Oncology, St James University Hospital, Leeds, UK.
© LitMetric 2025. All rights reserved.